Funding Opportunity RFA-NR-22-003 from the NIH Guide for Grants and Contracts. Persistent disparities in maternal health outcomes is a public health crisis that requires new insights and solutions. The purpose of this initiative is to support formative research and pilot studies to inform development of integrated models of care to prevent severe maternal morbidity and mortality among disproportionately impacted populations.

Funding Opportunity RFA-NR-22-002 from the NIH Guide for Grants and Contracts. Persistent disparities in maternal health outcomes is a public health crisis that requires new insights and solutions. The purpose of this initiative, advancing integrated models (AIM) of care, is to support intervention research that addresses structural inequities and reduces disparities in severe maternal morbidity and mortality. More specifically, this initiative seeks to advance the development, implementation, and evaluation of integrated models of care to prevent adverse maternal health outcomes among disproportionately impacted populations.

Funding Opportunity PAR-22-078 from the NIH Guide for Grants and Contracts. This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

in the region of £49,500 to £54,500: Wellcome Sanger Institute: We have a new opportunity for a Work Stream Manager to provide expert project management support to two to three of the Global Alliance for Genomic... Cambridge, Cambridgeshire

Notice NOT-DE-22-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NR-22-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to identify and evaluate the ongoing and long-term impacts of the COVID-19 pandemic, focusing specifically on governmental (local, state, tribal, federal) policy and programmatic actions that address two specific social determinants of health: food/nutrition security and housing security. Applications are requested to examine how these food/nutrition and housing policies and programs aimed at lessening the effects of the pandemic impacted health and health equity in individuals, families, and communities from health disparity populations. Health disparity populations include Blacks/African Americans, Hispanics/Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities.

Notice NOT-MH-22-150 from the NIH Guide for Grants and Contracts

Competitive: Hyper Recruitment Solutions (HRS): We are currently looking for an experience RNA Biologist to join a cutting edge RNA Therapeutic Biotechnology company based in the Cambridge area. This novel... Cambridgeshire

Notice NOT-OD-22-064 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-115 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-19-135 The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits and provide insights into cellular interactions that underlie brain function. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell and circuit specific tools will require extensive focused research designed to remove barriers to delivery of gene therapies. In addition to identification and removal of barriers, the need to specifically target dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cutting edge tools have been developed for use in model organisms, primarily rodents, fish and flies. These cutting edge tools, such as viral delivery of genetic constructs, are increasingly adaptable to large brains and more importantly are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains, more directly relevant to the human brain is the focus of this initiative. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged.

Notice NOT-CA-22-043 from the NIH Guide for Grants and Contracts

Notice NOT-DK-22-003 from the NIH Guide for Grants and Contracts

£46,199-£55,341 per annum: Wellcome Sanger Institute: The Human Genetics Programme at the Wellcome Sanger Institute is driving a step-change in our understanding of genetic causes and biological mechan... Cambridgeshire (GB)

Notice NOT-AA-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-23-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

Funding Opportunity RFA-HL-23-011 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-23-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-23-013 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Funding Opportunity RFA-HL-23-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.